RePORT International Resources

The Mayo Clinic Center for Tuberculosis webinar library features recorded sessions covering diagnostics, treatment, prevention, and comorbidities, aimed at expanding individuals' knowledge and skills in tuberculosis care.

This monthly webinar series offers healthcare professionals the latest insights in tuberculosis (TB). Tuberculosis experts will discuss screening, diagnosis, and treatment of TB disease and latent TB infection (LTBI). Topics include considerations for pediatric and adult populations, clinical updates, diagnostic methods, and treatment strategies. Healthcare professionals managing patients with TB can stay informed on research developments and emerging treatment regimens for active TB and LTBI, exploring innovative approaches to enhance patient adherence and outcomes.

This webinar explores mycobacterial diagnostic tools and their applications in TB prevention and treatment. Learn to effectively use and interpret Tuberculin Skin Tests (TSTs), interferon-gamma release assays (IGRAs), and cultures for diagnosing latent TB infection (LTBI) and active TB disease. Case studies will highlight real-world challenges and best practices for leveraging these tools in clinical practice.

Tuberculosis (TB) in pregnancy poses serious risks to both mother and fetus if not promptly diagnosed and managed. This webinar covers key aspects of TB diagnosis, treatment, and complications during pregnancy. Participants will also be introduced to the TB Pregnancy Toolkit and other resources to support effective care for pregnant patients.

This webinar explores how molecular testing and imaging support TB diagnosis by enhancing accuracy, speeding detection, and guiding effective treatment decisions. This course is designed for allied health professionals, nurses, nurse practitioners, physicians, physician assistants, resident/fellows, and healthcare professionals working in a public healthcare setting. Learning Objectives Identify essential tools for TB diagnosis Describe molecular testing methods Explain imaging roles in TB diagnosis

McGill TBcentre - many webinars and mini courses (all prerecorded)

TSTin4D and IGRAin4D are both are decision aids providing information about the likelihood of developing TB disease, dying from TB, as well as post-TB disability, in the next 20 years in a person with a positive tuberculin skin test or a positive Interferon gamma release assay and a known risk factor. This also provides information on the potential benefits and risks of TB preventive therapy. Also added is information for the person considering whether to accept TB preventive therapy, including a handout that includes predictions for them, and some basic information about TB prevention.

The BCG World Atlas is designed to be a useful resource for clinicians, policymakers, and researchers alike, providing information that may be helpful for better interpretation of TB diagnostics as well as design of new TB vaccines. For example, BCG practices can impact the results of the tuberculin skin test, the most widely used test for latent TB infection, and past BCG policies and practices may be as or more important than current policies in interpreting TST results in adults or in deciding when alternative tests for latent TB infection, such as interferon-g release assays (IGRAs), may be preferable to TST. If novel TB vaccines complement the existing BCG vaccine, it would be relevant to know what previous BCG vaccination individuals have had, how many, and at what ages prior to administering novel ‚ booster vaccines.‚Äô In summary, the BCG World Atlas provides the TB community with a useful resource through an open-access and easy-to-use website.

DEADLINE FOR APPLICATION: 1 November 2026 The Department of Laboratory Medicine at Memorial Sloan Kettering Cancer Center offers a two-year Clinical Microbiology Fellowship. This fellowship offers training for doctoral-level scientists interested in acquiring knowledge and skills necessary to direct a clinical microbiology laboratory. The fellowship will provide both general training in clinical microbiology as well as specialized training for diagnostic microbiology in immunocompromised patients. The fellow will obtain training in all subspecialties of clinical microbiology and develop knowledge of both conventional and molecular diagnostic methods for identification and antimicrobial susceptibility testing of bacteria, mycobacteria, fungi, and rapid detection of viruses and parasites. Additionally, the fellow will develop skills in laboratory management, clinical consultation related to microbiology and infectious diseases and interpretation, and clinical correlation of laboratory data. A strong emphasis is also placed on laboratory research, diagnostic assays development, and outcome studies in immunocompromised patients.

The Open Global Health Library provides a set of interesting research compounds free of charge. You decide which infectious disease you are targeting and which experimental setup you are using. By providing this compound library free of charge we aim to support researchers worldwide to identify new approaches to treat life-threatening infectious diseases especially in low and middle income countries. We provide a preselected collection of small molecules as chemical starting points to enable drug screening against the infectious disease of your interest and to enable you to identify the next life-changing infectious disease drug.

The Jimmy and Rosalynn Carter Humanitarian Award is presented annually by the National Foundation for Infectious Diseases (NFID) to honor individuals whose outstanding humanitarian efforts and achievements have contributed significantly to improving global public health through domestic and/or international activities. Priority is given to contributions in the area of infectious diseases. Selection criteria include: Humanitarian service; Public education contributions; and/or Legislative or policy achievements. Nominations for the 2027 NFID Jimmy and Rosalynn Carter Humanitarian Award will open in 2027.

The Maxwell Finland Award for Scientific Achievement is presented annually by the National Foundation for Infectious Diseases (NFID) to honor scientists who have made outstanding contributions to the understanding of infectious diseases and public health. Selection criteria include: Excellence in clinical and/or research activities; Participation in the training of future leaders in the field; and Positive impact on global public health through domestic and/or international activities. Nominations for the 2027 Maxwell Finland Award for Scientific Achievement will open in 2027.

This course requires about 40 total hours to complete. It is self-paced, has open enrollment, and can be accessed for 60 days.

This notice of funding opportunity (NOFO) invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. This mechanism may also be used to support development of a new resource to the broader scientific community of the National Institute of Allergy and Infectious Diseases (NIAID). It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate.The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.

Conference takes place October 14-16, 2026 in Manipal, India. Registration now open! Organized in partnership by Nature Medicine, Nature Microbiology, Nature Health, Nature Communications, and MAHE, this conference will bring together leading voices in infectious disease research to explore innovative solutions to global health challenges. As the world faces rising threats from emerging pathogens, climate change, and antimicrobial resistance, the event will highlight advances in surveillance, diagnostics, drug development, and vaccination strategies. Program highlights include: Disease surveillance, modelling and forecasting Antimicrobial resistance and drug development Challenges in diagnostic and screening Disease prevention strategies Future of vaccination and disease eradication Climate change and One Health approaches Pandemic preparedness

Applications for the third round of the New York State Biodefense Commercialization Fund are now closed. Please check back for updates on the program. The $40 million Biodefense Commercialization Fund was created to encourage and accelerate the development and commercialization of solutions for serious infectious disease threats, including COVID-19 and its variants, while fostering the creation of new life science businesses and supporting industry growth. The Fund has offered grants to startup companies and academic institutions that are developing promising diagnostics, vaccines, therapeutics, and such other innovations as epidemiological surveillance tools, environmental controls, and clinical care advances that address or mitigate infectious disease threats. For the current application period, New York State seeks applications focusing on the specific areas of interest: - Novel platforms for development of rapid Point-of-Care (POC) diagnostics (examples include, but are not limited to, CRISPR and/or Isothermal-based platforms) with priority given to POC diagnostics that can perform as well as or better than existing lab tests. - Processes that integrate easy-to-use sample preparation and allow for access in low resourced settings. - Novel tools for sequencing and serology-based tests that support infectious disease and pathogen surveillance

The Small Business Innovation Research (SBIR) Program is an important funding mechanism that the National Institutes of Health (NIH) uses to develop innovative solutions that address public health challenges. A major objective of the program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This Notice of Funding Opportunity (NOFO) invites SBIR grant applications from SBCs to support later-stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and which will require eventual Federal regulatory approval/clearance. The purpose of this NOFO and the resulting Phase IIB awards is to assist applicants in pursuing the milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners. Projects proposed under this NOFO MUST be relevant to the NHLBI mission (see B. Scientific/Technical Scope). This NOFO is specifically intended to benefit clinical practice by accelerating the commercialization of novel products that require ultimate approval/clearance by a Federal regulatory agency. This NOFO will give competitive preference and funding priority to applications deemed likely to result in a clinically-relevant commercial product as indicated by the applicant’s ability to secure independent third-party investor funds that equal or exceed the requested NHLBI funds, and competitive preference and funding priority to applications that show a strong potential for clinically relevant commercial products, as evidenced by the applicant’s ability to secure independent third-party investor funds equal to or exceeding the total requested costs. Please refer to the website for detail announcement and key dates.

The specimen repositories are a collaboration between the ACTG, IMPAACT, and HVTN clinical trial networks to make the large body of specimens collected for HIV research available to investigators.Several trials include TB outcomes. Please refer to the website for the details.

ClinRegs is an online database of country-specific clinical research regulatory information designed to assist in planning and implementing international clinical research. Countries are included based on NIAID's international clinical research priorities.

The Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) program supports the evaluation of early-stage diagnostics and novel diagnostic strategies for TB, in TB endemic countries to address an urgent need for improved tuberculosis (TB) diagnostics. Please refer to the website for the details